Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The SILVA Study: Survival in an International Phase III Prospective Randomized LD Small Cell Lung Cancer Vaccination Study With Adjuvant BEC2 and BCG

NCT00037713 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00037713
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00037713 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The SILVA Study: Survival in an International Phase III Prospective Randomized LD Small Cell Lung Cancer Vaccination Study With Adjuvant BEC2 and BCG
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Completed
Start date
September 30, 1998
Completion date
October 31, 2002
Enrollment
515 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, small cell lung